The Impact of Race and Diabetes on Mortality among Breast Cancer Patients by Alim, Jibril
Georgia State University
ScholarWorks @ Georgia State University
Public Health Theses School of Public Health
5-12-2017
The Impact of Race and Diabetes on Mortality
among Breast Cancer Patients
Jibril Alim
Follow this and additional works at: https://scholarworks.gsu.edu/iph_theses
This Thesis is brought to you for free and open access by the School of Public Health at ScholarWorks @ Georgia State University. It has been accepted
for inclusion in Public Health Theses by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact
scholarworks@gsu.edu.
Recommended Citation








































































































































































































In	 presenting	 this	 thesis	 as	 a	 partial	 fulfillment	 of	 the	 requirements	 for	 an	 advanced	
degree	 from	Georgia	 State	University,	 I	 agree	 that	 the	 Library	of	 the	University	 shall	make	 it	
available	for	inspection	and	circulation	in	accordance	with	its	regulations	governing	materials	of	
this	type.	I	agree	that	permission	to	quote	from,	to	copy	from,	or	to	publish	this	thesis	may	be	
granted	by	 the	 author	or,	 in	 his/her	 absence,	 by	 the	professor	 under	whose	direction	 it	was	
written,	or	 in	his/her	 absence,	by	 the	Associate	Dean,	 School	of	Public	Health.	 Such	quoting,	


































































































































































































































































































































































































































































































































































































































































































































Age	 	 	 	
	 50.07	 44.86	 <0.0001	











BMI	 	 	 	
	 26.86	 29.67	 <0.0001	















































































Age	 	 	 	
	 62.35	 59.57	 <0.0001	

















BMI	 	 	 	
	 32.00	 33.13	 <0.0001	






















































































Age	 	 	 	
	 67.73	 62.53	 <0.0001	














	 56.36	 50.42	 <0.0001	
BMI	 	 	 	
	 26.96	 29.83	 <0.0001	














































	 White	 African-American/Black	 P-Value	
Age	 	 	 	
	 67.36	 60.71	 <0.0001	














	 55.99	 50.60	 0.0024	
BMI	 	 	 	
	 26.23	 28.91	 <0.0001	





























































































































Mean	Age	 	 	 	














	 58.77	 50.41	 0.0019	
BMI	























Age	First	Diagnosed	with	Diabetes	 	 	 	
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	 Table	4.12	displays	the	racially	stratified	adjusted	hazard	ratios	of	breast	cancer	specific	
mortality	and	all-cause	mortality	with	accompanying	95%	confidence	intervals	for	the	specified	
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covariates	in	models	conducted	using	all	women	with	breast	cancer.	Model	1	assesses	all-cause	
mortality	as	an	endpoint.	Controlling	for	BMI,	diabetes	diagnosis,	and	pre-existing	diabetes	the	
age	category	of	35-64	was	associated	with	a	2.853	(2.641-3.081	95%	CI)	times	higher	and	the	
65+	age	category	was	associated	with	a	2.397	(2.226-2.581	95%	CI)	times	higher	hazard	of	
mortality	from	any	cause	than	the	18-34	age	group,	among	white	women.	Controlling	for	all	
other	covariates,	the	BMI	category	of	underweight	was	associated	with	a	0.838	(0.803-0.874	
95%	CI)	time	lower	and	the	BMI	category	of	overweight	was	associated	with	a	0.759	(0.747-
0.772	95%	CI)	times	lower	hazard	of	mortality	from	any	cause	than	the	BMI	category	of	normal	
weight	among	white	women.	The	BMI	category	of	Obese	was	associated	with	a	1.041	(1.023-
1.059	95%	CI)	times	higher	hazard	of	mortality	from	any	cause	than	the	BMI	category	of	normal	
weight	among	white	women.	Controlling	for	all	other	co-variates,	diabetes	diagnosis	was	
associated	with	1.377	(1.353-1.402	95%	CI)	times	higher	hazard	of	mortality	from	any	cause	
than	not	having	a	diabetes	diagnosis,	among	white	women.	Controlling	for	all	other	co-variates,	
pre-existing	diabetes	was	associated	with	a	1.079	(1.055-1.105	95%	CI)	times	higher	hazard	of	
mortality	from	any	cause	than	not	having	pre-existing	diabetes,	among	white	women.		
	 Due	to	a	lack	of	sufficient	data,	the	18-34	age	group	was	not	used	as	the	referent	group	
among	black	women.	Controlling	for	BMI,	diabetes	diagnosis,	and	pre-existing	diabetes	the	age	
category	of	65+	was	associated	with	a	1.050	(1.703-2.000	95%	CI)	times	higher	hazard	of	
mortality	from	any	cause	than	the	35-64	age	group,	among	African-American/Black	women.	
Controlling	for	all	other	covariates,	the	BMI	categories	of	underweight,	overweight,	and	obese	
were	associated	with	a	0.877	(0.764-1.006	95%	CI),	0.046	(0.040-0.053	95%	CI),	and	0.047	
(0.041-0.054	95%	CI)	respectively,	times	lower	hazard	of	mortality	from	any	cause	that	the	BMI	
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category	of	normal,	among	African-American/Black	women.	Controlling	for	all	other	co-
variates,	diabetes	diagnosis	was	associated	with	a	15.575	(14.156-17.136	95%	CI)	times	higher	
hazard	of	mortality	from	any	cause	than	not	having	a	diabetes	diagnosis,	among	black	women.	
Controlling	for	all	other	co-variates,	pre-existing	diabetes	was	associated	with	a	13.658	(12.443-
14.992	95%	CI)	times	higher	hazard	of	mortality	from	any	cause	than	not	having	pre-existing	
diabetes,	among	African-American/Black	women.		
	 Model	2	assesses	breast	cancer	specific	mortality	as	an	endpoint.	Controlling	for	BMI,	
diabetes	diagnosis,	and	pre-existing	diabetes	the	age	category	of	35-64	was	associated	with	a	
1.845	(1.703-2.000	95%	CI)	times	higher	and	the	65+	age	category	was	associated	with	a	0.753		
(0.698-0.813	95%	CI)	times	lower	hazard	of	mortality	from	breast	cancer	than	the	18-34	age	
group,	among	white	women.	Controlling	for	all	other	covariates,	the	BMI	category	of	
underweight	was	associated	with	a	0	(0-2.365e14	95%	CI)	time	lower	and	the	BMI	category	of	
overweight	was	associated	with	a	0.698	(0.679-0.718	95%	CI)	times	lower	hazard	of	mortality	
from	breast	cancer	than	the	BMI	category	of	normal	weight	among	white	women.	The	BMI	
category	of	Obese	was	associated	with	a	1.024	(0.996-1.052	95%	CI)	times	higher	hazard	of	
mortality	from	breast	cancer	than	the	BMI	category	of	normal	weight	among	white	women.	
Controlling	for	all	other	co-variates,	diabetes	diagnosis	was	associated	with	1.125	(1.093-1.158	
95%	CI)	times	higher	hazard	of	mortality	from	breast	cancer	than	not	having	a	diabetes	
diagnosis,	among	white	women.	Controlling	for	all	other	co-variates,	pre-existing	diabetes	was	
associated	with	a	0.850	(0.818-0.884	95%	CI)	times	lower	hazard	of	mortality	from	breast	
cancer	than	not	having	pre-existing	diabetes,	among	white	women.	
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Due	to	a	lack	of	sufficient	data,	the	18-34	age	group	was	not	used	as	the	referent	group	
among	black	women.	Controlling	for	BMI,	diabetes	diagnosis,	and	pre-existing	diabetes	the	age	
category	of	65+	was	associated	with	a	0.190		(0.175-0.206	95%	CI)	times	lower	hazard	of	
mortality	from	breast	cancer	than	the	35-64	age	group,	among	African-American/Black	women.	
Controlling	for	all	other	covariates,	the	BMI	categories	of	underweight,	overweight,	and	obese	
were	associated	with	a	0	(0-3.664e35	95%	CI),	0.020	(0.017-0.023	95%	CI),	and	0.010	(0.009-
0.01295%	CI)	respectively,	times	lower	hazard	of	mortality	from	breast	cancer	that	the	BMI	
category	of	normal,	among	African-American/Black	women.	Controlling	for	all	other	co-
variates,	diabetes	diagnosis	was	associated	with	a	10.891	(9.763-12.150	95%	CI)	times	higher	
hazard	of	mortality	from	breast	cancer	than	not	having	a	diabetes	diagnosis,	among	black	
women.	Controlling	for	all	other	co-variates,	pre-existing	diabetes	was	associated	with	a	7.696	
(6.936-8.540	95%	CI)	times	higher	hazard	of	mortality	from	breast	cancer	than	not	having	pre-
existing	diabetes,	among	African-American/Black	women.		
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Chapter	V	
Discussion	
The	Data	abstracted	from	the	2006-2009	NHIS	adult	surveys	showed	that	generally,	
African-American/Black	women	and	White	women	differ	in	their	prevalence	of	characteristics	
of	interest	regarding	diabetes	and	cancer.	White	women	are	older,	have	lower	BMIs	and	
smaller	proportions	that	can	be	considered	overweight	(26.61%)	or	obese	(29.45%),	and	a	
lower	prevalence	of	diabetes	(8.10%)	than	African-American/Black	women	(27.82%overweight,	
44.58%	obese,	12.68%	diabetic).	However,	White	women	had	a	higher	prevalence	of	general	
cancer	(11.21%)	as	well	as	breast	cancer	(3.18%)	than	African-American/Black	women	(4.67%	
and	1.69%)	respectively.	This	data	closely	resembles	the	general	trend	of	current	CDC	estimates	
of	obesity	prevalence	among	adult	White	women	(35.5%)	and	black	women	(56.9%)	and	
diabetes	prevalence	among	adult	White	(5.3%)	and	African-American/Black	women	(9.9%)	(CDC	
2014).		
	Among	women	with	diabetes,	across	both	racial/ethnic	groups,	individuals	were	older,	had	
higher	BMIs,	and	higher	rates	of	both	cancer	and	breast	cancer	than	the	general	female	
population.	However,	among	women	with	diabetes,	African-American/Black	women	showed	
trends	of	being	of	a	younger	age,	being	diagnosed	with	diabetes	earlier,	and	higher	proportions	
being	considered	obese.	Additionally,	African-American/Black	women	had	higher	proportions	
of	women	taking	medication	to	treat	their	diabetes	in	the	form	of	Insulin	or	diabetic	pills	than	
their	white	counterparts.		
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Women	with	breast	cancer	were	older	than	the	general	population,	with	similar	distributions	of	
BMI	categories	and	higher	prevalence	of	diabetes.	The	prevalence	of	diabetes	in	the	general	
population	of	women	was	8.10%	for	white	women	and	12.68%	for	African-American/Black	
women,	compared	to	13.87%	and	33.20%	for	White	and	African-American/Black	women	with	
breast	cancer.	This	indicates	that	diabetes	is	a	much	larger	concern	for	cancer	patients	than	the	
general	population,	especially	among	African-American/Black	women.	Among	women	with	
breast	cancer,	African-American/Black	women	were	younger,	diagnosed	with	breast	cancer	
younger,	had	higher	BMIs,	and	several	times	magnitude	higher	prevalence	of	diabetes	than	
White	women.		
	
Diabetes	and	Pre-existing	Diabetes	Rates	
				The	first	research	question	assessed	in	this	study	was	“Does	Diabetes	and	pre-existing	
diabetes	occurs	at	a	different	rate	among	African-American	women	with	breast	cancer	than	
White	women?”.	Statistical	analysis	showed	that	African-American/Black	women	with	did,	in	
fact,	have	a	higher	prevalence	of	diabetes	than	White	women	(33.20%	v	13.87%,	p	<0.0001).	
This	would	appear	to	be	intuitive	given	diabetes	higher	background	prevalence	in	the	general	
population	of	African-American	women	in	this	study	(12.68%),	however	the	prevalence	among	
women	with	breast	cancer	is	nearly	3	times	higher	than	the	prevalence	of	diabetes	in	the	
general	population	of	African-American	women	in	this	study	and	most	recent	CDC	estimates	
(9.9%).	Comparatively,	among	White	women,	the	prevalence	of	diabetes	also	increased	from	
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the	general	population	(8.10%)	to	the	population	of	White	women	with	breast	cancer	(13.87%),	
but	not	to	the	same	magnitude.		
				Among	women	with	breast	cancer	and	diabetes,	the	rate	of	pre-existing	diabetes	was	higher	
among	African-American/Black	women	than	in	White	women	(52.24%	v	39.82%,	p	<0.0001).	
There	was	no	significant	difference	in	mean	years	of	diabetes	prior	to	breast	cancer	diagnosis,	
however	higher	proportions	of	African-American	women	reported	having	diabetes	for	5-10	
years	(15.28%)	and	>10	years	(26.83%)	prior	to	breast	cancer	diagnosis	than	White	women	
(8.40%	and	17.54%	respectively).	Because	breast	cancer	develops	over	an	extended	period	of	
time,	pre-existing	diabetes	for	significant	lengths	of	time	suggests	a	biological	interaction	
between	the	diabetic	state	and	the	formation	of	breast	cancer.	Although	the	presence	of	
diabetes	5+	years	prior	to	breast	cancer	diagnosis	may	suggest	that	diabetes	played	a	role	in	
the	incipiency,	diabetes	at	any	stage	prior	to	diagnosis	may	still	impact	the	malignancy	by	
accelerating	the	growth	of	the	tumor.	This	study’s	findings	that	a	higher	proportion	of	African-
American/Black	women	with	breast	have	diabetes	(33.20%)	than	White	women	with	breast	
cancer	(13.87%)	supports	previous	studies	in	the	literature	that	suggest	that	breast	cancer	
patients	with	diabetes	are	more	likely	to	be	of	non-white	racial/ethnic	groups	(J.	Luo,	et	al.,	
2015)	although	the	magnitude	differs	significantly	from	what	has	been	put	forth,	5.5%	of	White	
women	with	breast	cancer	having	diabetes	and	11.3%	of	African-American/Black	(Wu,	et	al.,	
2015).		
Diabetes	and	All-Cause/Breast	Cancer	Specific	Mortality	
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The	next	set	of	research	questions	addressed	whether	diabetes	and	pre-existing	diabetes	is	
associated	with	increased	all-cause	and	breast	cancer-specific	mortality.	In	the	adjusted	Cox	
proportional	hazard	model	for	all-cause	mortality	among	all	women	with	breast	cancer,	
diabetes	was	associated	with	an	increased	hazard	of	death	from	any	cause	(HR:	1.603,	1.577-
1.630	95%	CI).	Among	diabetic	women	with	breast	cancer,	pre-existing	diabetes	was	associated	
with	an	increased	hazard	of	death	from	any	cause	(HR:	1.157,	1.109-1.206	95%	CI).		
Overall,	diabetes	increases	the	risk	of	all-cause	mortality.	This	study	identified	a	hazard	ratio	of	
1.603.	Studies	by	(J.	Luo,	et	al.,	2015)	also	identified	similar	increased	risks	of	all-cause	mortality	
(HR:	1.57),	another	study	identified	an	adjusted	HR	of	1.26(need	to	find	citation).	BMI	is	
associated	with	increased	mortality	at	all	categories.	Interestingly,	underweight	has	the	highest	
hazard	ratio	compared	to	normal	weight.	Although	higher	BMI	could	indicate	additional	health	
problems	that	are	associated	with	obesity,	including	more	severe	diabetes,	weight	loss	is	also	a	
result	of	both	cancer	progression	and	cancer	treatment.		
In	the	adjusted	Cox	proportional	hazard	model	for	breast	cancer	specific	mortality	among	all	
women	with	breast	cancer,	diabetes	was	associated	with	an	increased	hazard	of	death	from	
any	cause	(HR:	1.340,	1.305-1.375	95%	CI).	Among	diabetic	women	with	breast	cancer,	pre-
existing	diabetes	did	not	meet	stepwise	model	selection	criteria.	However,	among	all	women	
with	breast	cancer,	pre-existing	diabetes	was	associated	with	an	increased	risk	of	breast	cancer-
specific	mortality	as	well	(HR:	1.177,	1.138-1.217	95%	CI).		
Few	studies	have	been	conducted	on	the	relationship	between	breast	cancer-specific	mortality	
and	diabetes.	A	recently	conducted	study	using	the	WHI	identified	an	insignificant	relationship	
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between	diabetes	and	breast	cancer-specific	mortality,	HR:	.74	(0.52-1.02	95%	CI)	(J.	Luo,	et	al.,	
2014).	Conversely,	this	study	identified	a	significant	relationship	between	diabetes	and	breast	
cancer-specific	mortality,	HR:	1.375.	Studies	have	found	that	women	with	diabetes	are	more	
likely	to	have	hormone	negative	tumors	and	advanced	tumor	stage,	which	is	a	plausible	
explanation	the	increase	in	breast	cancer	specific	mortality.	However,	the	significance	of	race	as	
a	factor	even	among	diabetic	breast	cancer	patients	may	indicate	that	other	factors	in	the	
environment,	behaviors,	or	genetic	biology	of	African-American	women	lead	to	more	
aggressive	malignancies.		
	
	
Race	and	All-Cause/Breast	Cancer	Specific	Mortality	
				The	next	set	of	research	questions	addressed	the	impact	of	race	on	all-cause	and	breast	
cancer-specific	mortality.	In	the	adjusted	Cox	proportional	hazard	model	for	all-cause	mortality	
among	all	women	with	breast	cancer,	the	racial	classification	of	African-American/Black	was	
associated	with	an	increased	hazard	of	death	from	any	cause.	African-American/Black	women	
were	10%	more	likely	(HR:	1.102,	1.076-1.130	95%	CI)	to	die	from	any	cause	when	compared	to	
White	women.	Among	diabetic	women	with	breast	cancer,	African-American	women	were	less	
likely	to	die	from	any	cause	(HR:	0.741,	0.711-0.773	95%	CI).		
				In	the	adjusted	Cox	proportional	hazard	model	for	breast	cancer	specific	mortality	among	all	
women	with	breast	cancer,	African-American/Black	women	were	27%	more	likely	(HR:	1.269,	
1.228-1.312	95%	CI)	to	die	from	breast	cancer	than	White	women.	Among	diabetic	women	with	
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breast	cancer,	African-American/Black	women	were	56%	more	likely	(HR:	1.564,	1.465-1.669	
95%	CI)	to	die	from	breast	cancer	than	White	women.		
				Throughout	the	literature,	an	increase	in	mortality	has	been	shown	for	African-American	
women	compared	to	White	women.	However,	this	study	showed	a	differential	effect	of	race,	
increasing	the	risk	of	death	from	all-causes	in	African-American	women	compared	to	White	
women,	yet	decreasing	that	risk	among	diabetic	patients.	However,	the	hazard	ratio	of	
mortality	from	breast	cancer	increased	from	1.269	(all	breast	cancer	patients)	to	1.564	(diabetic	
breast	cancer	patients)	indicating	that	diabetes	impacts	the	progression	of	cancer,	and	
furthermore	that	impact	has	a	greater	impact	on	African-American	women.	This	may	be	due	to	
many	factors	including	differences	in	treatment	and	differences	in	cancer	biology.		
Impact	of	Diabetes	on	All-Cause	and	Breast	Cancer	Specific	Mortality	among	White	Women	v	
Black	Women	
Diabetes,	Race,	and	All-Cause/Breast	Cancer	Specific	Mortality	
				The	final	set	of	research	questions	assessed	how	the	impact	of	diabetes	differed	on	the	all-
cause	and	breast	cancer-specific	mortality	between	African-American	and	White	women.	The	
models	run	by	stratifying	breast	cancer	specific	and	all-cause	mortality	by	racial	classification	
(Table	4.12)	showed	that	diabetes	diagnosis	does	significantly	raise	the	risk	of	mortality	for	
both	African-American	and	White	women.	However,	diabetes	and	pre-existing	diabetes	show	
differential	effects	across	each	race.	Both	diabetes	and	pre-existing	diabetes	increase	the	risk	of	
all-cause	mortality	in	each	race.	However,	the	magnitude	is	several	times	larger	for	African	
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American	women	(adjusted	Diabetes	HR:	15.575,	adjusted	Pre-existing	HR:	13.658)	than	for	
White	women	(adjusted	Diabetes	HR:	1.377,	adjusted	Pre-existing	HR:	1.079).		
				In	the	modeling	of	breast	cancer-specific	mortality	stratified	by	race,	diabetes	was	shown	to	
increase	the	risk	of	mortality	for	both	races;	however,	pre-existing	diabetes	conferred	a	
protective	effect	on	white	breast	cancer	patients	while	increasing	mortality	risk	for	African-
American	breast	cancer	patients.	Similar	to	the	model	of	all-cause	mortality,	the	association	of	
diabetes	and	pre-existing	diabetes	with	breast	cancer-specific	mortality	was	several	times	
larger	for	African	American	women	(adjusted	Diabetes	HR:	1.891,	adjusted	Pre-existing	
HR:7.696)	than	it	was	for	White	women	(adjusted	Diabetes	HR:	1.125,	adjusted	Pre-existing	HR:	
0.850).		
Strengths	and	Limitations	
Weaknesses	in	this	study:	This	study	is	based	on	the	NHIS	which	is	a	self-report	survey	and	is	
subject	to	recall	bias	as	well	as	classification	error.		Studies	using	cancer	registries	would	be	
more	accurate	and	verifiable	as	well	as	more	comprehensive	in	reporting	of	cancer	
characteristics.	This	study	was	unable	to	control	for	characteristics	of	breast	cancer	that	may	
impact	mortality,	such	as	histology,	stage,	and	hormone	receptor	status.	This	study	was	unable	
to	assess	breast	cancer	treatments	and	how	these	may	impact	survival.		Because	the	NHIS	is	
meant	to	provide	estimates	on	the	prevalence	of	health-related	characteristics	in	the	US,	this	
data	could	not	adequately	assess	the	incidence	of	breast	cancer	among	diabetics.	Additionally,	
this	study	was	unable	to	abstract	information	such	as	education,	income,	and	health	insurance	
status	that	may	impact	treatment	and	diagnosis	of	both	breast	cancer	and	diabetes.		
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BMI	in	this	study	is	at	the	time	of	survey	not	at	the	time	of	diagnosis	with	cancer,	so	BMI	may	
be	influenced	by	cancer	progression	and	/or	lifestyle	changes	made	by	the	individual.	
Strengths	in	this	study:	At	the	time	the	analysis	was	done,	this	was	one	of	2	studies	to	assess	
how	diabetes	affects	mortality	in	African-American/Black	women.	The	NHIS	is	designed	to	be	
nationally	representative,	so	this	study	provides	robust	estimates	of	the	prevalence	of	the	
selected	characteristics	and	statistical	significance	of	the	associations	identified.		
	
Implications	
Diabetes	is	highly	prevalent	among	African-American/Black	breast	cancer	patients.	Moreover,	
African-American/Black	women	are	more	likely	to	have	pre-existing	diabetes	upon	breast	
cancer	diagnosis	than	White	women.	Diabetes	increases	both	all-cause	and	breast	cancer-
specific	mortality	among	both	African-American/Black	and	White	breast	cancer	patients.	
However,	it	appears	to	increase	the	disparity	in	hazard	of	death	between	the	two	racial	groups.	
Diabetes	may	develop	in	individuals	who	already	have	breast	cancer.	However,	Pre-existing	
diabetes	is	a	significant	contributor	to	mortality	from	all	causes	as	well	as	breast	cancer	
specifically.	Thus,	prevention	and	control	of	diabetes	may	help	slow	the	progression	of	breast	
cancer	and	decrease	the	likelihood	of	mortality,	particularly	among	African-American	women.		
Additionally,	specified	treatment	guidelines	may	be	needed	for	diabetic	breast	cancer	patients	
to	aid	in	mitigating	the	increased	mortality	among	this	group.		
Future	studies	
		 71	
				Case-Control	studies	could	be	conducted	to	ascertain	if	diabetes	associated	with	the	
development	of	more	aggressive	sub-types	of	breast	cancer.	This	study	and	others	showed	that	
diabetes	is	associated	with	an	increase	in	cancer	mortality;	however,	the	exact	mechanism	
remains	unclear.	Additionally,	longitudinal	studies	on	black	women’s	health	can	be	used	to	
assess	the	incidence	of	breast	cancer	among	both	diabetics	and	non-diabetics.	Studies	that	link	
to	SEER	registries	for	better	accuracy.	Future	studies	would	also	include	clinical	follow-ups	to	
assess	how	controlled	and	uncontrolled	diabetes	impact	mortality,	and	BMI	at	the	time	of	
cancer	diagnosis.	Future	studies	could	also	analyze	the	impact	of	diabetes	on	treatment	
selection	and	treatment	outcomes.	
Conclusion	
This	study	contributes	significantly	to	the	literature	by	providing	additional	data	on	the	co-
morbidity	of	diabetes	and	breast	cancer.	Specifically,	this	study	assessed	the	impact	this	co-
morbidity	has	on	African-American/Black	women.		African-American/Black	women	have	
disproportionately	high	breast	cancer	mortality	rates,	and	by	identifying	the	role	that	a	
common	co-morbidity	may	have	on	that	mortality	rate,	this	study	contributes	to	the	body	of	
literature	aimed	at	decreasing	this	disparity.	Interventions	aimed	at	decreasing	the	prevalence	
of	diabetes	among	breast	cancer	patients	and	emphasis	on	controlling	diabetic	severity	among	
breast	cancer	patients,	specifically	African-Americans	may	lead	to	improvements	in	prognosis.	
Additionally,	this	study	added	to	the	literature	indicating	that	diabetic	medication	may	have	a	
protective	effect	on	all-cause	and	breast	cancer-specific	mortality	among	cancer	patients.		
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